Table 5.
New BCR inhibitors in development in NHL
| Patient population | Type of NHL | Clinicaltrials.gov # | Reference | |
|---|---|---|---|---|
| BTK inhibitors | ||||
| ACP-196 (Acerta Pharma) | R/R | ABC DLBCL MCL FL |
NCT02112526 NCT02213926 NCT02180711 |
|
| AVL-292 (Avila Therapeutics, Inc.) | R/R | B-cell NHL & WM | NCT10351935 | Brown45 |
| ONO-4059 (Ono Pharmaceutical Co.) | R/R | ABC DLBCL | NCT01659255 | Dyer16 |
| BGB-3111 (BeiGene) | R/R | B-cell NHL | NCT02343120 | |
| PI3K inhibitors | ||||
| Duvelisib (PI3Kγ/δ, Infinity Pharmaceuticals) R-bendamustine & Duvelisib R-Duvelisib vs. R-placebo |
R/R R/R R/R |
Hematologic malignancies Indolent NHL Phase 3, FL |
NCT01476657 NCT01871675 NCT02204982 |
Flinn24 Flinn37 |
| BKM-120 (Pan-PI3K, Novartis) BKM-120 R-BKM-120 |
R/R R/R R/R |
All NHL All NHL All NHL |
NCT01693614 NCT01719250 NCT02049541 |
Younes20 |
| Bay80-6946 (Bayer) | R/R | All NHL | NCT01660451 | |
| RP6530 (PI3Kγ/δ, Rhizen Pharmaceuticals) | R/R | Hematologic Malignancies | NCT02017613 | |
| GDC0941 (PI3Kα/δ, Genentech) | R/R | All NHL | NCT00876122 | |
| TGR-1202 (PI3Kδ, TG Therapeutics) | R/R | MCL All NHL |
NCT02268851 NCT02006485 |
|
| XL147 (Pan-PI3K, Sanofi) | R/R | All NHL | NCT00486135 | Brown46 |
| SYK inhibitors | ||||
| Entospletinib (GS-9973, Gilead) | R/R | FL | Sharman47 | |
| PKC inhibitors | ||||
| AEB071 (Novartis) | R/R | DLBCL | NCT01402440 | |